Download PDF
Clin Colon Rectal Surg 2013; 26(02): 128-134
DOI: 10.1055/s-0033-1348052
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Biologic Therapy and Surgery for Crohn Disease

E. Carter Paulson
1   Department of Surgery, Philadelphia VA Medical Center, Philadelphia, Pennsylvania
› Author Affiliations
Further Information

Publication History

Publication Date:
27 June 2013 (online)

Also available at
    Permissions and Reprints

Abstract

In 1998, infliximab, an antitumor necrosis factor alpha (anti-TNF-α) antibody, was approved for use in the treatment of Crohn disease (CD). Since then, other biologic therapies, including adalimumab and certolizumab pegol (newer anti-TNF-α antibodies), and natalizumab, an antibody against alpha-4 integrin, have also been approved. Here, we review the published studies that examine the relationship between pre- and postoperative biologic therapy and postoperative complications in patients with CD. This body of literature is composed of numerous small, retrospective, heterogeneous studies that demonstrate conflicting and varied results. Overall, the receipt of biologic therapy in the pre- or postoperative period does not appear to significantly increase the risk of postoperative complications. It is, however, difficult to draw any firm conclusions based on the existing level of data. In the future, larger prospective studies are needed to better elucidate the true risks, if any, that the use of biologic therapy poses to patients with CD requiring operation.

Keywords

Crohn disease - surgery - biologic therapy - postoperative complications
 

  • References

  • 1 Rutgeerts PJ. Review article: the limitations of corticosteroid therapy in Crohn's disease. Aliment Pharmacol Ther 2001; 15 (10) 1515-1525
    CrossrefPubMedGoogle Scholar
  • 2 Lichtenstein GR, Feagan BG, Cohen RD , et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4 (5) 621-630
    CrossrefPubMedGoogle Scholar
  • 3 Toruner M, Loftus EV, Harmsen WS , et al. Risks factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterol 2008; 134: 929-936
    CrossrefPubMedGoogle Scholar
  • 4 Post S, Betzler M, von Ditfurth B, Schürmann G, Küppers P, Herfarth C. Risks of intestinal anastomoses in Crohn's disease. Ann Surg 1991; 213 (1) 37-42
    CrossrefPubMedGoogle Scholar
  • 5 Yamamoto T, Allan RN, Keighley MR. Risk factors for intra-abdominal sepsis after surgery in Crohn's disease. Dis Colon Rectum 2000; 43 (8) 1141-1145
    CrossrefPubMedGoogle Scholar
  • 6 Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003; 125 (2) 320-327
    CrossrefPubMedGoogle Scholar
  • 7 Tzivanakis A, Singh JC, Guy RJ, Travis SPL, Mortensen NJ, George BD. Influence of risk factors on the safety of ileocolic anastomosis in Crohn's disease surgery. Dis Colon Rectum 2012; 55 (5) 558-562
    CrossrefPubMedGoogle Scholar
  • 8 Colombel JF, Loftus Jr EV, Tremaine WJ , et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004; 99 (5) 878-883
    CrossrefPubMedGoogle Scholar
  • 9 Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg 2008; 12 (10) 1730-1736 , discussion 1736–1737
    CrossrefPubMedGoogle Scholar
  • 10 Indar AA, Young-Fadok TM, Heppell J, Efron JE. Effect of perioperative immunosuppressive medication on early outcome in Crohn's disease patients. World J Surg 2009; 33 (5) 1049-1052
    CrossrefPubMedGoogle Scholar
  • 11 Canedo J, Lee SH, Pinto R, Murad-Regadas S, Rosen L, Wexner SD. Surgical resection in Crohn's disease: is immunosuppressive medication associated with higher postoperative infection rates?. Colorectal Dis 2011; 13 (11) 1294-1298
    CrossrefPubMedGoogle Scholar
  • 12 Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34 (8) 1081-1085
    CrossrefPubMedGoogle Scholar
  • 13 Arts J, D'Haens G, Zeegers M , et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004; 10 (2) 73-78
    CrossrefPubMedGoogle Scholar
  • 14 Gutierrez-Ureña S, Molina JF, García CO, Cuéllar ML, Espinoza LR. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39 (2) 272-276
    CrossrefPubMedGoogle Scholar
  • 15 Mahadevan U, Loftus Jr EV, Tremaine WJ , et al. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis 2002; 8 (5) 311-316
    CrossrefPubMedGoogle Scholar
  • 16 Subramanian V, Pollok RC, Kang JY, Kumar D. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br J Surg 2006; 93 (7) 793-799
    CrossrefPubMedGoogle Scholar
  • 17 Pinna-Pintor M, Arese P, Bona R , et al. Severe steroid-unresponsive ulcerative colitis: outcomes of restorative proctocolectomy in patients undergoing cyclosporin treatment. Dis Colon Rectum 2000; 43 (5) 609-613 , discussion 613–614
    CrossrefPubMedGoogle Scholar
  • 18 Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 2001; 60 (3) 214-217
    CrossrefPubMedGoogle Scholar
  • 19 Bridges Jr SL, Moreland LW. Perioperative use of methotrexate in patients with rheumatoid arthritis undergoing orthopedic surgery. Rheum Dis Clin North Am 1997; 23 (4) 981-993
    CrossrefPubMedGoogle Scholar
  • 20 Perhala RS, Wilke WS, Clough JD, Segal AM. Local infections complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. Arthritis (Egypt) 1991; 34 (2) 146-152
    CrossrefPubMedGoogle Scholar
  • 21 Sands BE, Anderson FH, Bernstein CN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350 (9) 876-885
    CrossrefPubMedGoogle Scholar
  • 22 Hanauer SB, Feagan BG, Lichtenstein GR , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002; 359: 15411549
    PubMedGoogle Scholar
  • 23 Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008; 23 (1) CD006893
    PubMedGoogle Scholar
  • 24 Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106 (4) 644-659 , quiz 660
    CrossrefPubMedGoogle Scholar
  • 25 Rutgeerts PJ, D'Haens G, Targan S , et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117 (4) 761-769
    CrossrefPubMedGoogle Scholar
  • 26 Keane J, Gershon S, Wise RP , et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345 (15) 1098-1104
    CrossrefPubMedGoogle Scholar
  • 27 Colombel JF, Loftus Jr EV, Tremaine WJ , et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126 (1) 19-31
    CrossrefPubMedGoogle Scholar
  • 28 Hansen RA, Gartlehner G, Powell GE, Sandler RS. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol 2007; 5 (6) 729-735
    CrossrefPubMedGoogle Scholar
  • 29 Cottone M, Kohn A, Daperno M , et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9 (1) 30-35
    CrossrefPubMedGoogle Scholar
  • 30 Marchal L, D'Haens G, Van Assche G , et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther 2004; 19 (7) 749-754
    CrossrefPubMedGoogle Scholar
  • 31 Appau KA, Fazio VW, Shen B , et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg 2008; 12 (10) 1738-1744
    CrossrefPubMedGoogle Scholar
  • 32 White EC, Melmed GY, Vasiliauskas E , et al. Does preoperative immunosuppression influence unplanned hospital readmission after surgery in patients with Crohn's disease?. Dis Colon Rectum 2012; 55 (5) 563-568
    CrossrefPubMedGoogle Scholar
  • 33 Kumar A, Auron M, Aneja A, Mohr F, Jain A, Shen B. Inflammatory bowel disease: perioperative pharmacological considerations. Mayo Clin Proc 2011; 86 (8) 748-757
    CrossrefPubMedGoogle Scholar
  • 34 Beddy D, Dozois EJ, Pemberton JH. Perioperative complications in inflammatory bowel disease. Inflamm Bowel Dis 2011; 17 (7) 1610-1619
    CrossrefPubMedGoogle Scholar
  • 35 Rutgeerts P. Review article: recurrence of Crohn's disease after surgery - the need for treatment of new lesions. Aliment Pharmacol Ther 2006; 24 (Suppl. 03) 29-32
    CrossrefPubMedGoogle Scholar
  • 36 Michelassi F, Balestracci T, Chappell R, Block GE. Primary and recurrent Crohn's disease. Experience with 1379 patients. Ann Surg 1991; 214 (3) 230-238 , discussion 238–240
    CrossrefPubMedGoogle Scholar
  • 37 El-Hachem S, Regueiro M. Postoperative Crohn's disease: prevention and treatment. Expert Rev Gastroenterol Hepatol 2009; 3 (3) 249-256
    CrossrefPubMedGoogle Scholar
  • 38 Fernandez-Blanco I, Monturiol J, Martinez B , et al. Adalimumab in the prevention of postoperative recurrence of Crohn's disease. Gastroenterology 2010; 138: S-692
    PubMedGoogle Scholar
  • 39 Regueiro M, Schraut W, Baidoo L , et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009; 136 (2) 441-450 , e1, quiz 716
    CrossrefPubMedGoogle Scholar
  • 40 Regueiro M, El-Hachem S, Kip KE , et al. Postoperative infliximab is not associated with an increase in adverse events in Crohn's disease. Dig Dis Sci 2011; 56 (12) 3610-3615
    CrossrefPubMedGoogle Scholar